Scientific article

Chemotherapeutic options in the management of anal cancer

Published inExpert opinion on pharmacotherapy, vol. 5, no. 12, p. 2479-2484
Publication date2004

During the past two decades, anal cancer has served as a paradigm for the successful application of chemoradiation to solid tumours; so far, it remains one of the few carcinomas of the gastrointestinal tract which are curable without the need for definitive surgery. Since the original contribution by Nigro in 1974, surprisingly few changes have been made to the standard of care in chemotherapy, which still consists of a combination of 5-fluorouracil and mitomycin C. However, many issues have yet to be clarified, such as the potential role of cisplatin as a substitute to mitomycin, as well as treatment-induced toxicity in HIV-positive patients. In this paper, the management of patients with anal cancer is presented, and new chemotherapeutic options are critically reviewed. Finally, the authors' opinion regarding currently unresolved issues in the treatment of these rare neoplasms is expressed.

  • Anus Neoplasms/therapy
  • Carcinoma, Squamous Cell/complications/therapy
  • Cisplatin/therapeutic use
  • Combined Modality Therapy
  • Fluorouracil/therapeutic use
  • HIV Seropositivity/complications
  • Humans
  • Mitomycin/therapeutic use
Citation (ISO format)
GERVAZ, Pascal et al. Chemotherapeutic options in the management of anal cancer. In: Expert opinion on pharmacotherapy, 2004, vol. 5, n° 12, p. 2479–2484. doi: 10.1517/14656566.5.12.2479
Main files (1)
Article (Published version)
ISSN of the journal1465-6566

Technical informations

Creation11/11/2014 3:46:00 PM
First validation11/11/2014 3:46:00 PM
Update time03/14/2023 10:14:20 PM
Status update03/14/2023 10:14:20 PM
Last indexation01/16/2024 2:22:21 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack